Fundraising FoxVensana Capital — 2020 Investments
6 investments dated 2020 · listed companies and verified rows first · show all
CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.
BiotechHealthtechMedical DevicesAustin, US
Craig Palmer(Executive Officer)inNadim Yared(Executive Officer, Director)inDean Bruhn-Ding(Executive Officer)inJohn Brintnall(Executive Officer)inLiz Galle(Executive Officer)Kevin Hykes(President, Chief Executive Officer & Director)in
Board seatKirk Nielsen· per SEC Form D
Co-investorsABS VenturesHatteras Venture PartnersNew Enterprise Associates (NEA)Treo Ventures, LlcWindham Capital PartnersYsios Capital+1 more
Senseonics develops and commercializes Eversense, an implantable continuous glucose monitoring system designed to measure blood sugar levels for up to one year in people with diabetes, offering an alternative to conventional glucose monitors that require more frequent sensor replacement.
BiotechGermantown, US
Mukul Jain(Executive Officer)Francine R. Kaufman(Executive Officer, Director)inRick Sullivan(Executive Officer)inKenneth L Horton(Executive Officer)Timothy T. Goodnow(Executive Officer, Director)Mirasol Panlilio(Executive Officer)in
Board seatPeter Justin Klein· per SEC Form D · $30M raise · filed Sep 2020
Co-investorsNew Enterprise Associates (NEA)Roche Venture Fund
SpyGlass Pharma develops a sustained drug delivery platform for treating chronic ophthalmic diseases such as glaucoma, integrating drugs, procedures, and devices for long-term disease control and vision preservation.
BiotechHealthtechMedical DevicesAliso Viejo, US
Glenn Sussman(Co-founder)inMalik Y. Kahook(Co-founder)inPatrick Mooney(CEO)
BoardJake Merrill(Director)Geoff Pardo(Director)Bilal Khan(Director)
Board seatKirk Nielsen· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)RA CapitalSamsara BioCapitalSands Capital Ventures
A precision oncology company providing genomic testing and resources to support cancer care decisions, operating under Labcorp Oncology.
BiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Executive Officer, Director, Promoter)inLuis A. Diaz, Jr.(Executive Officer, Director, Promoter)Sam Angiuoli(Executive Officer)inSian Jones(Executive Officer)inLisa Kann(Executive Officer)inAnthony Newton(Executive Officer)
Board seatJustin Klein· per SEC Form D
Co-investors3B Future Health FundCatalio Capital Management, LPCo-Win VenturesNew Enterprise Associates (NEA)Windham Capital Partners
Relievant offers the Intracept Procedure, a minimally invasive, FDA-cleared medical intervention designed to relieve chronic low back pain caused by vertebrogenic pain.
Medical DevicesRedwood City, US
Alex DiNello(Executive Officer, Director)
BoardRichard Mott(Director)Brent Ahrens(Director)inJason Lettman(Director)John Ryan(Director)
Board seatJustin Klein· per SEC Form D
Co-investorsCanaan PartnersEmergent Medical Partners, LLPEndeavour VisionLightstone VenturesNew Enterprise Associates (NEA)Morgenthaler
BiotechRichmond, US
Michael D. Grisham(Chief Executive Officer)in
Co-investorsAmgen Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.